Cargando…

Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery

Pentacyclic triterpenoids are well-known phytochemicals with various biological activities commonly found in plants as secondary metabolites. The wide range of biological activities exhibited by triterpenoids has made them the most valuable sources of pharmacological agents. A number of novel triter...

Descripción completa

Detalles Bibliográficos
Autores principales: Khwaza, Vuyolwethu, Mlala, Sithenkosi, Oyedeji, Opeoluwa O., Aderibigbe, Blessing A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122576/
https://www.ncbi.nlm.nih.gov/pubmed/33918996
http://dx.doi.org/10.3390/molecules26092401
_version_ 1783692655426797568
author Khwaza, Vuyolwethu
Mlala, Sithenkosi
Oyedeji, Opeoluwa O.
Aderibigbe, Blessing A.
author_facet Khwaza, Vuyolwethu
Mlala, Sithenkosi
Oyedeji, Opeoluwa O.
Aderibigbe, Blessing A.
author_sort Khwaza, Vuyolwethu
collection PubMed
description Pentacyclic triterpenoids are well-known phytochemicals with various biological activities commonly found in plants as secondary metabolites. The wide range of biological activities exhibited by triterpenoids has made them the most valuable sources of pharmacological agents. A number of novel triterpenoid derivatives with many skeletal modifications have been developed. The most important modifications are the formation of analogues or derivatives with nitrogen-containing heterocyclic scaffolds. The derivatives with nitrogen-containing heterocyclic compounds are among the most promising candidate for the development of novel therapeutic drugs. About 75% of FDA-approved drugs are nitrogen-containing heterocyclic moieties. The unique properties of heterocyclic compounds have encouraged many researchers to develop new triterpenoid analogous with pharmacological activities. In this review, we discuss recent advances of nitrogen-containing heterocyclic triterpenoids as potential therapeutic agents. This comprehensive review will assist medicinal chemists to understand new strategies that can result in the development of compounds with potential therapeutic efficacy.
format Online
Article
Text
id pubmed-8122576
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81225762021-05-16 Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery Khwaza, Vuyolwethu Mlala, Sithenkosi Oyedeji, Opeoluwa O. Aderibigbe, Blessing A. Molecules Review Pentacyclic triterpenoids are well-known phytochemicals with various biological activities commonly found in plants as secondary metabolites. The wide range of biological activities exhibited by triterpenoids has made them the most valuable sources of pharmacological agents. A number of novel triterpenoid derivatives with many skeletal modifications have been developed. The most important modifications are the formation of analogues or derivatives with nitrogen-containing heterocyclic scaffolds. The derivatives with nitrogen-containing heterocyclic compounds are among the most promising candidate for the development of novel therapeutic drugs. About 75% of FDA-approved drugs are nitrogen-containing heterocyclic moieties. The unique properties of heterocyclic compounds have encouraged many researchers to develop new triterpenoid analogous with pharmacological activities. In this review, we discuss recent advances of nitrogen-containing heterocyclic triterpenoids as potential therapeutic agents. This comprehensive review will assist medicinal chemists to understand new strategies that can result in the development of compounds with potential therapeutic efficacy. MDPI 2021-04-21 /pmc/articles/PMC8122576/ /pubmed/33918996 http://dx.doi.org/10.3390/molecules26092401 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Khwaza, Vuyolwethu
Mlala, Sithenkosi
Oyedeji, Opeoluwa O.
Aderibigbe, Blessing A.
Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery
title Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery
title_full Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery
title_fullStr Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery
title_full_unstemmed Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery
title_short Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery
title_sort pentacyclic triterpenoids with nitrogen-containing heterocyclic moiety, privileged hybrids in anticancer drug discovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122576/
https://www.ncbi.nlm.nih.gov/pubmed/33918996
http://dx.doi.org/10.3390/molecules26092401
work_keys_str_mv AT khwazavuyolwethu pentacyclictriterpenoidswithnitrogencontainingheterocyclicmoietyprivilegedhybridsinanticancerdrugdiscovery
AT mlalasithenkosi pentacyclictriterpenoidswithnitrogencontainingheterocyclicmoietyprivilegedhybridsinanticancerdrugdiscovery
AT oyedejiopeoluwao pentacyclictriterpenoidswithnitrogencontainingheterocyclicmoietyprivilegedhybridsinanticancerdrugdiscovery
AT aderibigbeblessinga pentacyclictriterpenoidswithnitrogencontainingheterocyclicmoietyprivilegedhybridsinanticancerdrugdiscovery